☆ 4.6 Article

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Hematology

CEBPA mutations in AML site matters Comment

Lars Bullinger

Summary: In this retrospective analysis of 4708 AML cases, the impact of CEBPA mutations on prognosis was evaluated. It was found that in-frame mutations affecting the bZIP region of CEBPA have a favorable outcome, regardless of whether they occur as biallelic or single mutations. This study highlights the previously undefined role of CEBPA bZIP mutations, which are associated with distinct disease biology, including younger age, higher white blood cell counts, the presence of GATA2 mutations, and high complete remission rates and long-term survival.

BLOOD (2022)

Add to Collection

Article Hematology

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Satoshi Wakita et al.

Summary: Mutations of CCAAT/enhancer-binding protein alpha (CEBPAmu) significantly impact the prognosis of acute myeloid leukemia (AML). Particularly, CEBPAmu in the basic leucine zipper domain (bZIP) is strongly associated with a favorable prognosis and can serve as a potent marker for AML prognosis. This finding has implications for treatment stratification and the development of targeted therapeutic approaches in CEBPA-mutated AML.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Joseph D. Khoury et al.

Summary: This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms, emphasizing the refinement of diagnostic criteria and the importance of actionable biomarkers, while maintaining global applicability.

LEUKEMIA (2022)

Add to Collection

Review Oncology

Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells

Jialan Niu et al.

Summary: This review summarizes the resistance mechanisms of leukemia stem cells (LSCs) and the crucial role of the bone marrow microenvironment in LSCs resistance in acute myeloid leukemia (AML), providing better strategies for future research on eradicating LSCs and clinical treatment of AML.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

Curtis A. Lachowiez et al.

Summary: This study analyzed the clinical and molecular characteristics of AML patients with IDH1 and IDH2 mutations treated with venetoclax and examined the impact of co-occurring NPM1 mutations. The results showed that the detrimental effect of IDH1 mutation can be partially abrogated with venetoclax-based therapy. Co-occurring NPM1 mutations play an important role in the treatment and prognosis of IDH1 and IDH2 or NPM1 mutated AML.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Oncology

Current status and future perspectives in targeted therapy of NPM1-mutated AML

Roberta Ranieri et al.

Summary: NPM1 mutations are the most common genetic alteration in AML, and NPM1-mutated AML is regarded as a distinct genetic entity. This study provides an overview of potential targeted therapies against NPM1-mutated AML, including strategies to interfere with oligomerization and abnormal traffic of NPM1, induce protein degradation, and target nucleolar structure integrity. Therapeutic results with BCL-2 inhibitor and menin inhibitors, as well as immunotherapeutic approaches, are also discussed.

LEUKEMIA (2022)

Add to Collection

Article Hematology

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Tatjana Pandzic et al.

Summary: This article discusses the clinical significance of small TP53 clones detected in chronic lymphocytic leukemia using next generation sequencing (NGS), and proposes a robust diagnostic algorithm for safely detecting and reporting TP53 variants with variant allele frequency (VAF) as low as 5%.

HEMASPHERE (2022)

Add to Collection

Letter Oncology

Male predominance in AML is associated with specific preleukemic mutations

Aviv De-Morgan et al.

LEUKEMIA (2021)

Add to Collection

Article Multidisciplinary Sciences

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia

Brooks A. Benard et al.

Summary: This study aggregates multiple AML cohorts to explore the correlation between clonal abundance of somatic mutations and clinical outcomes. High variant allele frequency for certain mutations is associated with poor prognosis, while increased GATA2 variant allele frequency correlates with better outcomes. Clinical features such as white blood cell count and blast percentage are related to the subclonal abundance of mutations like TP53 and IDH1.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Rosa Ayala et al.

Summary: Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that DNMT3A or EZH2 mutations were associated with a better response to azacytidine, while NRAS and TP53 variants were linked to shorter overall survival. Mutated BCOR was found to shorten relapse-free survival. Patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy according to subgroup analyses.

CANCERS (2021)

Add to Collection

Review Oncology

Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia

Noortje van Gils et al.

Summary: Standard induction chemotherapy is the first-line therapy for AML, but many patients face relapse or refractory disease. AML relapse is caused by therapy-resistant leukemia cells, with LSCs being considered the origin. The different states of treatment persisters and LSCs can be exploited to achieve optimal therapy response.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis

Monica Hellesoy et al.

Summary: The incidence, molecular presentation, and outcome of AML are influenced by sex, with significant molecular differences observed between female and male patients, including prevalence of co-occurring mutations in female AML. While FLT3-ITD mutations are overrepresented in female patients, males with FLT3-ITDs have additional mutations in RNA splicing and epigenetic modifier genes. Sex-specific considerations could improve prognostication, prediction, and therapeutic strategies in AML.

MOLECULAR ONCOLOGY (2021)

Add to Collection

Article Hematology

Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

Claudia Sargas et al.

Summary: NGS has been introduced for genetic variation detection in AML, but implementation in clinical routine faces challenges in assay diversity and variant reporting criteria. The PETHEMA group established a nationwide network of reference laboratories to address this challenge and provide molecular results in clinics. Technical cross-validation results and clinical validation in 823 samples of AML patients showed an increase in overall concordance from 60.98% to 85.57% after consensus and optimization, demonstrating the feasibility of a harmonized NGS analysis and reporting network for AML patients.

HAEMATOLOGICA (2021)

Add to Collection

Review Hematology

Treatment for Relapsed/Refractory Acute Myeloid Leukemia

Felicitas Thol et al.

Summary: Patients with relapsed or refractory AML have poor prognosis and allogeneic HSCT is the only curative treatment. Mutational analysis guides treatment selection, with novel agents targeting mutations in FLT3, IDH, and TP53 showing promising results. Combination therapies and further trials are ongoing to optimize treatment outcomes.

HEMASPHERE (2021)

Add to Collection

Article Hematology

Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy

Jing Ni et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)

Add to Collection

Review Oncology

Advances in targeted therapy for acute myeloid leukemia

Jifeng Yu et al.

BIOMARKER RESEARCH (2020)

Add to Collection

Meeting Abstract Hematology

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Guangrong Qin et al.

BLOOD (2020)

Add to Collection

Article Hematology

Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia

Torsten Haferlach

HEMATOLOGY REPORTS (2020)

Add to Collection

Editorial Material Hematology

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

Ross L. Levine et al.

HAEMATOLOGICA (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Mechanisms of drug resistance in acute myeloid leukemia

Jing Zhang et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection

Review Oncology

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Michael Leisch et al.

CANCERS (2019)

Add to Collection

Article Oncology

Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics

Anna Petrackova et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Review Oncology

Targeting FLT3 mutations in AML: review of current knowledge and evidence

Naval Daver et al.

LEUKEMIA (2019)

Add to Collection

Article Hematology

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

Victoria V. Prassek et al.

HAEMATOLOGICA (2018)

Add to Collection

Review Biochemistry & Molecular Biology

What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies

Yann Guillermin et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Article

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling

Katherine Tarlock et al.

Oncotarget (2018)

Add to Collection

Article Hematology

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

Victoria V. Prassek et al.

HAEMATOLOGICA (2018)

Add to Collection

Review Oncology

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use

Ulrike Bacher et al.

BLOOD CANCER JOURNAL (2018)

Add to Collection

Article Hematology

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features

Francesco Mannelli et al.

HAEMATOLOGICA (2017)

Add to Collection

Article Hematology

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features

Francesco Mannelli et al.

HAEMATOLOGICA (2017)

Add to Collection

Review Oncology

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

Lars Bullinger et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Pathology

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists

Lawrence J. Jennings et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2017)

Add to Collection

Article Pathology

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors

Rajyalakshmi Luthra et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2017)

Add to Collection

Review Hematology

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

David Grimwade et al.

BLOOD (2016)

Add to Collection

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Education, Scientific Disciplines

Mutations in AML: prognostic and therapeutic implications

Courtney D. DiNardo et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)

Add to Collection

Article Medicine, Research & Experimental

Current practices and guidelines for clinical next-generation sequencing oncology testing

Samuel P. Strom et al.

Cancer Biology & Medicine (2016)

Add to Collection

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Multidisciplinary Sciences

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Li Ding et al.

NATURE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.